# Acro Biomedical Co., LTD.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Acro Biomedical Co., LTD.).

## Overview

ACRO BIOMEDICAL CO., LTD. is a Nevada-incorporated microcap company that, following a 2017 change of control, pivoted from its prior business to developing and marketing nutritional products focused on wellness. Historically, it acted primarily as a trading/distribution business: purchasing cordyceps-related supplements from three suppliers in Taiwan and reselling to a small number of distributors/customers, mainly in Taiwan and Hong Kong. The company has not generated any sales since December 31, 2022 and, as of its 2025 filings, reported no orders and no active marketing or distribution arrangements. Operations have been funded largely through advances from a minority stockholder, with substantial going-concern uncertainty disclosed in its reports.

## Products & services

• Cordyceps-related nutritional products (dietary supplements)
• Distributor sales/wholesale fulfillment (historical)
• Product sourcing from Taiwanese suppliers (historical)
• Third-party inspection/testing/certification (planned)
• Prior product: metallothionein MT-3 elizer (discontinued)
• Prior R&D: proposed chicken feed supplement concept (not commercialized)

- **Cordyceps-based supplements** (90%) — Cordyceps-related wellness products historically purchased from Taiwan suppliers and resold to distributors.
- **Other nutritional products (non-cordyceps)** (5%) — Non-cordyceps supplement items sold historically (e.g., metallothionein MT-3 elizer) and potential future complementary products.
- **R&D / product development initiatives** (0%) — Exploratory development work (e.g., chicken feed supplement concept) that has not resulted in commercial products.
- **Sourcing and distribution services (trading model)** (5%) — Supplier sourcing, import/fulfillment, and wholesale distribution activities supporting product resale.

- Cordyceps-related nutritional products (dietary supplements)
- Distributor sales/wholesale fulfillment (historical)
- Product sourcing from Taiwanese suppliers (historical)
- Third-party inspection/testing/certification (planned)
- Prior product: metallothionein MT-3 elizer (discontinued)
- Prior R&D: proposed chicken feed supplement concept (not commercialized)

## Customers

Historically, ACRO sold primarily to a very small number of unrelated distributor-type customers rather than directly to end consumers. In 2022, two customers accounted for 100% of revenue (and 91.7% in 2021), highlighting extreme customer concentration and limited negotiating leverage. Customers were based in Taiwan and Hong Kong, and the company notes that these distributors were responsible for regulatory compliance in the countries where they resold products (including Taiwan, China and Hong Kong). As of the 2025 reports, the company had no current orders and no formal customer agreements, meaning any restart would require rebuilding a customer base and channels from scratch.

- **Supplement distributors (Taiwan)** (primary) — Purchase cordyceps-related products for wholesale distribution and resale in Taiwan and adjacent markets.
- **Supplement distributors (Hong Kong / China-linked channels)** (primary) — Buy products for resale through Hong Kong-based channels with downstream exposure to PRC consumer demand and policy conditions.
- **Potential new distributors/agents (international)** (emerging) — Prospective channel partners needed to restart sales given the lack of current marketing and distribution arrangements.

- Distributors in Taiwan buying cordyceps products for resale
- Distributors in Hong Kong selling into China/PRC end markets
- Highly concentrated customer base (two customers drove most sales)
- Customers buy for wellness/TCM-adjacent supplement demand
- No long-term customer contracts; purchases can stop at any time
- Channel partners handle local labeling/marketing compliance

## Geography

The company is headquartered in Fishers, Indiana (United States) but historically sourced products from suppliers in Taiwan and sold to customers located in Taiwan and Hong Kong. Management highlights that demand and sell-through were affected by China’s COVID-19 restrictions and political/legal conditions impacting Hong Kong, indicating meaningful indirect exposure to PRC end markets. The operating model depends on cross-border logistics and the ability of distributors to market products under local dietary supplement rules. No authoritative revenue-by-geography percentages were provided in the excerpts, and the company reported no sales since 2022, limiting the usefulness of a quantitative geographic split.

- Corporate base in Indiana, United States (Nevada corporation)
- Suppliers located in Taiwan (three suppliers historically)
- Customers historically in Taiwan and Hong Kong
- Downstream demand tied to China/PRC supplement market dynamics
- Cross-border shipping and customs/logistics are operational dependencies
- Regulatory regimes vary by country for dietary supplements

## Strategy

Near-term strategy is constrained by the absence of orders, inventory purchases since 2022, and reliance on related-party funding, making liquidity and business reactivation prerequisites. Management indicates a need to rebuild marketing and distribution channels and potentially hire sales/marketing personnel, as prior sales were driven by a non-full-time CEO. The product focus remains largely cordyceps-based supplements, with optionality to add complementary products, though no negotiations were underway per the filings. The company also intends to rely on third parties for inspection, verification, testing, and certification if it manufactures or outsources manufacturing, aiming to support compliance and product quality expectations.

- **Rebuild marketing and distribution channels** (short-term) — The company reports no current marketing/distribution arrangements and no orders, making channel development essential to restart revenue.
- **Stabilize financing and liquidity** (short-term) — Operations have been funded primarily by advances from a minority stockholder and the company discloses substantial doubt about going concern.
- **Broaden product offering beyond cordyceps** (medium-term) — A narrow product set increases sensitivity to changes in public tastes and category-specific demand shocks.

- Re-establish sales by rebuilding distributor relationships and channels
- Secure funding beyond minority-stockholder advances to sustain operations
- Maintain focus on cordyceps products while exploring complementary items
- Use third-party testing/certification to support compliance and quality
- Add sales/marketing capability beyond the CEO-led historical approach
- Reduce single-product dependence by expanding the product portfolio

## Risks

The dominant company-specific risk is going concern: ACRO has had no revenue since 2022, minimal cash, and relies on advances from a minority stockholder, with no assurance of continued funding. Commercial risk is elevated due to extreme historical customer concentration, lack of customer contracts, and the absence of current marketing/distribution arrangements. The business is also exposed to regulatory and compliance risk across jurisdictions for dietary supplements (labeling, purity, approvals), while product liability exposure is heightened by the disclosure that the company does not carry product liability insurance. Finally, the cross-border supply chain (Taiwan sourcing; China/Hong Kong-linked demand) creates geopolitical, logistics, and demand-disruption risks, including sensitivity to PRC policy actions and inflation/supply chain disruptions.

- **Going concern and inability to generate revenue** [critical] — The company reports no revenues since December 31, 2022, minimal cash, and substantial doubt about continuing as a going concern.
- **Reliance on related-party funding** [high] — Primary financing has been advances from a minority stockholder (and to a lesser extent the CEO) with no assurance of continuation.
- **Customer concentration and lack of customer agreements** [high] — Two customers represented 100% of 2022 revenue and 91.7% of 2021 revenue; customers can cease purchasing at any time.
- **Regulatory compliance for dietary supplements across countries** [high] — Each country has laws on purity, labeling, and approvals; inability to comply can block sales or trigger enforcement actions.
- **Geopolitical/policy disruption affecting Hong Kong/China-linked demand** [high] — Management cites impacts from China’s COVID-19 restrictions and political/legal situation in Hong Kong on sales and fundraising.
- **Supply chain and supplier dependency (Taiwan sourcing; no long-term contracts)** [medium] — No long-term supplier agreements and potential interruptions (transport, disasters) can raise costs or limit availability.
- **Product liability exposure without insurance** [medium] — The company discloses it does not have product liability insurance, increasing financial impact of any claims.

- Going-concern risk due to no sales since 2022 and minimal cash
- Dependence on minority stockholder advances; funding may stop
- Customer concentration and no contracts increase revenue volatility
- Regulatory risk for dietary supplements across multiple countries
- No product liability insurance increases downside from claims
- Supplier risk: no long-term supply agreements; price/quality uncertainty
- Geopolitical and policy risk tied to Hong Kong/China market conditions
- Bad-debt/collections risk evidenced by prior uncollectible receivables

## Accounting

Financial statements are highly sensitive to estimates and non-cash items because the company has minimal operating activity and limited balance sheet resources. A key judgmental area is collectability of receivables and credit-loss provisioning, highlighted by the $480,000 bad debt reserve recorded in 2023 for 2022 sales deemed uncollectible. Related-party financing introduces accounting complexity around imputed interest and classification of advances, which can materially affect reported interest expense and liabilities even when cash balances are nominal. Lease accounting can also influence reported liabilities and operating cash flow presentation, as changes in operating lease liabilities were cited in cash flow explanations.

- **Credit loss / bad debt provisioning (allowance for doubtful accounts)** — Can materially distort operating results and working-capital metrics in low-revenue periods.
- **Related-party financing and imputed interest** — Non-cash interest expense and liability balances may be significant relative to the company’s scale.
- **Lease accounting (operating lease liability movements)** — Impacts balance sheet leverage measures and operating cash flow reconciliation.

- Allowance for doubtful accounts can swing results (e.g., $480k reserve)
- Revenue recognition depends on distributor sales and collectability
- Related-party advances and imputed interest affect P&L and liabilities
- Lease liabilities/ROU accounting affects balance sheet and cash flow
- Liability forgiveness can create non-operating gains impacting comparability
- Going-concern disclosures affect classification/valuation considerations

---

*Last updated: 2026-08-11T04:46:17.035329+00:00*